脂质体阿霉素为主方案治疗高龄非霍奇金淋巴瘤的临床研究

目的观察脂质体阿霉素联合治疗高龄非霍奇金淋巴瘤患者的有效性和安全性。方法应用脂质体阿霉素联合COP为主的方案化疗或联合利妥昔单抗等其他治疗方案治疗34例患者．观察患者应用脂质体阿霉素过程中及其后的毒副反应及疗效。结果全组34例患者共接受176个疗程化疗，平均每个患者累计应用脂质体阿霉素127．0mg治疗．总有效率（CR＋PR）为88．2％（30／34），其中CR24例（70．6％），PR6例（17．7％），SD1例（2．9％），PD3例（8．8％）。毒副反应主要为骨髓抑制，未出现严重感染。心脏毒性发生率14．7％（5／34），无化疗相关死亡。结论脂质体阿霉素联合治疗高龄非霍奇金淋巴瘤具有较高的安全性和有效性。

Clinical study of doxorybicin hydrochloride liposome-containing regimens on elderly patients with non-Hodgkin＇s lymphoma

Objective To investigate the efficacy and safety of Doxorybicin Hydrochloride Liposome -containing Regimens. Methods 34 elderly patients with B-cell Non-Hodgkin＇s Lymphoma were treated with Doxorybicin Hydrochloride Liposome combining chemotherapy based COP regimen in our department. The efficacy and safety were evaluated during and after. Results The total cycle was 176 doses in the 34 patients. The total response rate was 88.3%（30/34）. And the side effect evaluations showed that 29 patients hadn＇t any reaction during and after the administration of Doxorybicin Hydrochloride Liposnme ,main symptoms were cardiopalmus, leucocytopenia associated with infusion. By these means, all the patients could tolerate and finish the therapy. Conclusions Doxoryhiein hydrochloride liposome -containing regimens have efficacy and safety in the therapy of elderly patients with B-cell NHL.